Clinical Trial Detail

NCT ID NCT04299880
Title Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Recruitment Enrolling by invitation
Gender both
Phase Phase I
Variant Requirements No
Sponsors Boston Biomedical, Inc
Indications

Advanced Solid Tumor

Therapies

Gemcitabine + Nab-paclitaxel + Napabucasin

Napabucasin

Bevacizumab

Napabucasin + Paclitaxel

Napabucasin + Nivolumab

Fluorouracil + Irinotecan + Leucovorin + Napabucasin

Age Groups: adult senior

No variant requirements are available.